Résultats et intérêt de l’utilisation de la toxine botulique dans l’hyperactivité détrusorienne idiopathique

Haab F, Amarenco G, Coloby P, et al. (2004) Terminology of lower urinary tract dysfunction: French adaptation of the terminology of the International Continence Society. Prog Urol 14(6): 1103–1111

Hashim H, Abrams P (2006) Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 175(1): 191–194

Milsom I, Stewart W, Thüroff J (2000) The prevalence of overactive bladder. Am J Manag Care 6(11 Suppl): S565–S573

Currie CJ, McEwan P, Poole CD, et al. (2006) The impact of the overactive bladder on health-related utility and quality of life. BJU Int 97(6): 1267–1272

Reeves P, Irwin D, Kelleher C, et al. (2006) The current and future burden and cost of overactive bladder in five European countries. Eur Urol 50(5): 1050–1057

Burgio KL (2004) Current perspectives on management of urgency using bladder and behavioral training. J Am Acad Nurse Pract 16(Suppl. 10): 4–7

Haab F, Castro-Diaz D (2005) Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract 59(8): 931–937

van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. (2007) Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 178(5): 2029–2034

Elhilali MM, Khaled SM, Kashiwabara T, et al. (2005) Sacral neuromodulation: long-term experience of one center. Urology 65(6): 1114–1117

Schurch B, Stöhrer M, Kramer G, et al. (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164(3 Pt 1): 692–697

Sahai A, Khan MS, Dasgupta P (2007) Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 177(6): 2231–2236

Hirst GR, Watkins AJ, Guerrero K, et al. (2007) Botulinum toxin-B is not an effective treatment of refractory overactive bladder. Urology 69(1): 69–73

Ghei M, Maraj BH, Miller R, et al. (2005) Effects of botulinum toxin-B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 174(5): 1873–1877

Dykstra D, Enriquez A, Valley M (2003) Treatment of overactive bladder with botulinum toxin type B: a pilot study. Int Urogynecol J Pelvic Floor Dysfunct 14(6): 424–426

Jeffery S, Fynes M, Lee F, et al. (2007) Efficacy and complications of intradetrusor injection with botulinum toxin-A in patients with refractory idiopathic detrusor overactivity. BJU Int 100(6): 1302–1306

Ghalayini IF, Al-Ghazo MA (2007) Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction. Neurourol Urodyn 26(4): 531–536

Karsenty G, Elzayat E, Delapparent T, et al. (2007) Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 177(3): 1011–1014

Kuo HC (2007) Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin-A for idiopathic detrusor overactivity. J Urol 178(4 Pt 1): 1359–1363

Kuo HC (2006) Will sub-urothelial injection of small dose of botulinum-A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 68(5): 993–997

Schulte-Baukloh H, Weiss C, Stolze T, et al. (2005) Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 48(6): 984–990

Kuschel S, Werner M, Schmid DM, et al. (2008) Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up. Int Urogynecol J Pelvic Floor Dysfunct 19(7): 905–909

Lee JC, Yokoyama T, Hwang HJ, et al. (2007) Clinical application of Clostridium botulinum type A neurotoxin purified by a simple procedure for patients with urinary incontinence caused by refractory destrusor overactivity. FEMS Immunol Med Microbiol 51(1): 201–211

Cohen BL, Rivera R, Barboglio P, Gousse A (2007) Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection. J Urol 177(3): 1006–1010

Lucioni A, Rapp DE, Gong EM, et al. (2006) Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection. Can J Urol 13(5): 3291–3295

Schmid DM, Sauermann P, Werner M, et al. (2006) Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176(1): 177–185

Neugart F, Groh R, Götz T, Horsch R (2006) Injections of botulinum toxin-A into the detrusor vesicae for treatment of refractory detrusor hyperactivity in non-neurological patients. Aktuelle Urol 37(3): 212–217

Kalsi V, Apostolidis A, Popat R, et al. (2006) Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 49(3): 528–535

Kalsi V, Popat RB, Apostolidis A, et al. (2006) Costconsequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 49(3): 519–527

Popat R, Apostolidis A, Kalsi V, et al. (2005) A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174(3): 984–989

Watanabe T, Saito M, Hirakawa S, Miyagawa I (2005) The effect of botulinum toxin injection into the bladder for overactive bladder: two cases. Nippon Hinyokika Gakkai Zasshi 96(4): 511–514

Smith CP, Nishiguchi J, O’Leary M, et al. (2005) Single-institution experience in 110 patients with botulinum toxin-A injection into bladder or urethra. Urology 65(1): 37–41

Smith CP, Chancellor MB (2005) Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol 19(7): 880–882

Kessler TM, Danuser H, Schumacher M, et al. (2005) Botulinum-A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 24(3): 231–236

Rajkumar GN, Small DR, Mustafa AW, Conn G (2005) A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 96(6): 848–845

Schulte-Baukloh H, Weiss C, Schobert J, et al. (2005) Subjective patient satisfaction after injection of botulinum- A toxin in detrusor overactivity. Aktuelle Urol 36:230–3

Schulte-Baukloh H, Weiss C, Stolze T, et al. (2005) Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 66(1): 82–87

Kuo HC (2005) Clinical effects of sub-urothelial injection of botulinum-A toxin on patients with non-neurogenic detrusor overactivity refractory to anticholinergics. Urology 66(1): 94–98

Werner M, Schmid DM, Schüssler B (2005) Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective non-randomized study. Am J Obstet Gynecol 192(5): 1735–1740

Guzmán S, Honeck P, Weiss J, et al. (2005) Botulinum toxin injection for neurogenic and no neurogenic bladder dysfunction. Arch Esp Urol 58(7): 651–655

Rapp DE, Lucioni A, Katz EE, et al. (2004) Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology 63(6): 1071–1075

Kuo HC (2004) Urodynamic evidence of effectiveness of botulinum-A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63(5): 868–872

Flynn MK, Webster GD, Amundsen CL (2004) The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol 172(6 Pt 1): 2316–2320

Harper M, Popat RB, DasGupta R, et al. (2003) A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 92: 325–326